Novo Excipients Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.20 M
as on 16-11-2024
- Company Age 21 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.00 Cr
as on 16-11-2024
- Revenue 66.15%
(FY 2023)
- Profit 107.93%
(FY 2023)
- Ebitda 67.58%
(FY 2023)
- Net Worth 73.06%
(FY 2023)
- Total Assets 43.82%
(FY 2023)
About Novo Excipients
The Corporate was formerly known as Active Drugs Systems Private Limited.. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹6.00 Cr.
Sonal Shah, Mona Doshi, Bimal Doshi, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230MH2003PTC142463
- Company No.
142463
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Oct 2003
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Novo Excipients Private Limited offer?
Novo Excipients Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Medicine, Antiallergic API, Hydroxypropyl Methylcellulose, Wall Putty, Powder Putty.
Who are the key members and board of directors at Novo Excipients?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gautam Shah  | Managing Director | 01-Oct-2003 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Bimal Doshi | Director | 14-Jun-2011 | Current |
| Sonal Shah | Director | 26-Aug-2011 | Current |
| Mona Doshi | Director | 26-Aug-2011 | Current |
Financial Performance of Novo Excipients.
Novo Excipients Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 66.15% increase. The company also saw a substantial improvement in profitability, with a 107.93% increase in profit. The company's net worth Soared by an impressive increase of 73.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Novo Excipients?
In 2023, Novo Excipients had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Metaverse Pharmaceuticals Private LimitedActive 2 years 7 monthsSonal Shah and Gautam Shah are mutual person
- Vitamystic Healthcare Private LimitedActive 2 years 11 months
Sonal Shah and Gautam Shah are mutual person
- Manmill Sciences Private LimitedActive 16 years 2 months
Sonal Shah and Gautam Shah are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 01 Jun 2018 | ₹6.00 Cr | Open |
How Many Employees Work at Novo Excipients?
Novo Excipients has a workforce of 107 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Novo Excipients, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Novo Excipients's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
